Edoxaban tosilate hydrate

USDailyMed:Edoxaban B01AF03(WHO) CA:℞-onlyUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide 480449-70-5N 10280735 7575 DB09075N 8456212N NDU3J18APO D09710N CHEBI:85973N DTXSID50197398 Interactive image CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13‍‍‍‍‍‍​​​‍​​​​​​-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1NKey:HGVDHZBSSITLCT-JLJPHGGASA-NN Edoxaban, sold under the brand nameLixianaamong others, is ananticoagulantmedication and adirect factor Xa inhibitor.It is takenby mouth. Compared withwarfarin, it has fewerdrug interactions,and does not require regular assessment of blood samples forprothrombin timeto assure safe anticoagulant therapy. It was developed byDaiichi Sankyoand approved in July 2011, in Japan for prevention ofvenous thromboembolismsfollowing lower-limborthopedic surgery.It was also approved in the United States by theFood and Drug Administration(FDA) in January 2015, for the prevention of stroke and non–central-nervous-system systemicembolism.It was approved for use in the European Union in June 2015.It is on theWorld Health Organization's List of Essential Medicines.